Jayaram Hari
Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom.
UCL Institute of Ophthalmology, London, United Kingdom.
Taiwan J Ophthalmol. 2020 Oct 21;10(4):255-258. doi: 10.4103/tjo.tjo_63_20. eCollection 2020 Oct-Dec.
The reduction of intraocular pressure is currently the only known modifiable risk factor for the treatment of Glaucoma, which is the leading cause of irreversible worldwide blindness. This concise review discusses the evidence underpinning the reduction of intraocular pressure in the treatment of glaucoma, the role of target intraocular pressure in clinical practice and appraises clinical data supporting the concept that every mmHg of intraocular pressure reduction is important in reducing the risk of developing glaucoma and the progression of existing disease. Every mmHg in IOP reduction is important, with evidence showing an impact on both functional and structural progression but does not however explain all glaucoma risk.
降低眼压是目前已知的治疗青光眼唯一可改变的风险因素,青光眼是全球不可逆失明的主要原因。这篇简要综述讨论了降低眼压治疗青光眼的相关证据、目标眼压在临床实践中的作用,并评估了支持以下观点的临床数据:眼压每降低1 mmHg对于降低青光眼发病风险和现有疾病进展都很重要。眼压每降低1 mmHg都很重要,有证据表明其对功能和结构进展均有影响,但这并不能解释所有的青光眼风险。